Outlook is bright in the medium term; ‘Neutral’ retained given expensive valuations and uncertain near-term recovery
Outlook is bright in the medium term; ‘Neutral’ retained given expensive valuations and uncertain near-term recovery
Impact of slippages in H2 to be limited; ICICIBC, HDFCB, SBIN and AUBANK are top picks
The bank plans to increase its focus on Retail, Agri, and MSME segments and aims to capture a higher wallet…
The Pfizer-BioNTech vaccine is priced at $19.5/dose in the US, while the Oxford-AstraZeneca vaccine is expected to be priced at…
Reduction in liquidity on B/S another trigger; vehicle financiers are best placed; FY22e EPS raised by 1-9%
However, valuations limit upside; coverage initiated with Neutral and TP of Rs 440
Considering other settlements, limited build-up of sales over FY23-26E, and unlimited quantities of g-Revlimid by Cipla post Jan-26E, there could…
Company continues to gain competitive ground; tariff hike imminent; Buy retained with target price of Rs 650
Its share of Ebit may be as high as 82% in FY23; ESG concerns are a overhang; earnings outlook muted;…
Weakness in top 2-10 client bucket a concern; positives factored in; ‘Neutral’ retained
We expect NMDC to restart operations from the Donimalai mine by December end and accordingly raise our FY21E/FY22E volume estimate…
Collection efficiency for the bank has been holding well, although the moratorium pool, which is yet to make any payments,…
Results indicate demand recovery is faster than expected; FY21/22 EPS up 10/3%; TP raised to Rs 1,420; ‘Neutral’ maintained
The sharp outperformance in the stock (aided by MSCI inclusion) when seen in the context of growth outlook and return…
The company is reorienting its SUV business to maintain its DNA and brand position and garner market share.
We interacted with the the V-Mart management to gain the latest insights on the developments and recovery in the Retail…
Global operations surprised positively while India missed estimates; FY22e EPS up 7% to factor in stronger revival in SMRPBV and…
India Ebitda up 15% y-y; higher LME & lower costs to boost profitability; valuations attractive; ‘Buy’ retained with TP of…